Telomere and cancer: What's more at the end?;Télomère et cancer: Quoi de plus à la fin?

Medecine/Sciences

Volumn 21, Issue 1, 2005, Pages 37-42

  Brunori, Michele ^a,b   Gilson, Eric ^a,b  

^a UNIVERSITÉ DE LYON   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOPROTEIN;

CARCINOGENESIS; CHROMOSOME; CHROMOSOME ANALYSIS; DNA DETERMINATION; ENZYME ANALYSIS; GENE FUNCTION; GENOME; HUMAN; REVIEW; TELOMERE;

EUKARYOTA;

EID: 12344328830     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200521137     Document Type: Review

References (29)

1. Cech TR. Beginning to understand the end of the chromosome. Cell 2004; 116: 273-9.
2. Masutomi K, Yu EY, Khurts S, et al. Telomerase maintains telomere structure in normal human cells. Cell 2003; 114: 241-53.
3. Gisselsson D. Chromosome instability in cancer: how, when, and why? Adv Cancer Res 2003; 87: 1-29.
4. O'Sullivan JN, Bronner MP, Brentnall TA, et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet 2002; 32: 280-4.
5. Artandi SE, Chang S, Lee SL, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000; 406: 641-5.
6. Rudolph KL, Millard M, Bosenberg MW, DePinho RA. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 2001; 28: 155-9.
7. Gabet AS, Mortreux F, Charneau P, et al. Inactivation of hTERT transcription by Tax. Oncogene 2003; 22: 3734-41.
8. Kim NW, Piatyszek MA, Prowse KR, et al. Specific associations of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-4.
9. Greenberg RA, Chin L, Femino A, et al. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell 1999; 97: 515-25.
10. Gonzalez-Suarez E, Samper E, Flores JM, Blasco MA. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat Genet 2000; 26: 114-7.
11. Farazi PA, Glickman J, Jiang S, et al. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res 2003; 63: 5021-7.
12. Hahn WC, Counter CM, Lundberg AS, et al. Creation of human tumour cells with defined genetic elements. Nature 1999; 400: 464-8.
13. Elenbaas B, Spirio L, Koerner F, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001; 15: 50-65.
14. Lundberg AS, Rondell SH, Stewart SA, et al. Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene 2002; 21: 4577-86.
15. Bryan TM, Englezou A, Dalla-Pozza L, et al. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997; 3: 1271-4.
16. Seger YR, Garcia-Cao M, Piccinin S, et al. Transformation of normal human cells in the absence of telomerase activation. Cancer Cell 2002; 2: 401-13.
17. Lazarov M, Kubo Y, Cai T, et al. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med 2002; 8: 1105-14.
18. Brun C, Marcand S, Gilson E. Proteins that bind to double-stranded regions of telomeric DNA. Trends Cell Biol 1997; 7: 317-24.
19. de Lange T. Protection of mammalian telomeres. Oncogene 2002; 21: 532-40.
20. Ancelin K, Brunori M, Bauwens S, et al. Targeting assay to study the cis functions of human telomeric proteins: evidence for inhibition of telomerase by TRF1 and for activation of telomere degradation by TRF2. Mol Cell Biol 2002; 22: 3474-87.
21. Miyachi K, Fujita M, Tanaka M, et al. Correlation between telomerase activity and telomeric-repeat binding factors in gastric cancer. J Exp Clin Cancer Res 2002; 21: 269-75.
22. Kondo T, Oue N, Yoshida K, et al. Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. Cancer Res 2004; 64: 523-9.
23. Aragona M, De Divitiis O, La Torre D, et al. Immunohistochemical TRF1 expression in human primary intracranial tumors. Anticancer Res 2001; 21: 2135-9.
24. Saito K, Vagihashi A, Nasu S, et al. Gene expression for suppressors of telomerase activity (telomeric-repeat binding factors) in breast cancer. Jpn J Cancer Res 2002; 93: 253-8.
25. Ohyashiki JH, Hayashi S, Yahata N, et al. Impaired telomere regulation mechanism by TRF1 (telomere-binding protein), but not TRF2 expression, in acute leukemia cells. Int J Oncol 2001; 18: 593-8.
26. Nakanishi K, Kawai T, Kumaki F, et al. Expression of mRNAs for telomeric repeat binding factor (TRF)-1 and TRF2 in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Clin Cancer Res 2003; 9: 1105-11.
27. Stewart SA, Hahn WC, O'Connor BF, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA 2002; 99: 12606-11.
28. Smith LL, Coller HA, Roberts JM. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol 2003; 5: 474-9.
29. Griffith JD, Comeau L, Rosenfield S, et al. Mammalian telomeres end in a large duplex loop. Cell 1999; 97: 503-14.